Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02836340 : TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Admission to the ICU after OHCA and successful CPR due to a cardiac cause

- Post anoxic coma on admission

- Ability to start study medication as soon as possible, but ultimately within 6h after
OHCA via a central venous line

- Age 18 years or older

- Eligible for treatment with a target temperature management of 36? C

Exclusion Criteria:

- No informed consent

- Known co-morbidity with a life expectancy of <6 months prior to cardiac arrest

- Women aged 49 or less

- Severe cognitive impairment (documented dementia) known prior to OHCA

- Inability to insert a central venous line
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557